Burke-Gaffney A - Search Results

1

Thioredoxin: friend or foe in human disease?

Burke-Gaffney A, Callister ME, Nakamura H. Burke-Gaffney A, et al. Trends Pharmacol Sci. 2005 Aug;26(8):398-404. doi: 10.1016/j.tips.2005.06.005. Trends Pharmacol Sci. 2005. PMID: 15990177 Review.

2

Regulation of chemokine expression in atherosclerosis.

Burke-Gaffney A, Brooks AV, Bogle RG. Burke-Gaffney A, et al. Vascul Pharmacol. 2002 May;38(5):283-92. doi: 10.1016/s1537-1891(02)00253-7. Vascul Pharmacol. 2002. PMID: 12487033 Review.

3

The RAGE axis in systemic inflammation, acute lung injury and myocardial dysfunction: an important therapeutic target?

Creagh-Brown BC, Quinlan GJ, Evans TW, Burke-Gaffney A. Creagh-Brown BC, et al. Intensive Care Med. 2010 Oct;36(10):1644-1656. doi: 10.1007/s00134-010-1952-z. Epub 2010 Jul 15. Intensive Care Med. 2010. PMID: 20631986 Review.

4

Increased plasma thioredoxin levels in patients with sepsis: positive association with macrophage migration inhibitory factor.

Leaver SK, MacCallum NS, Pingle V, Hacking MB, Quinlan GJ, Evans TW, Burke-Gaffney A. Leaver SK, et al. Intensive Care Med. 2010 Feb;36(2):336-41. doi: 10.1007/s00134-009-1640-z. Epub 2009 Sep 15. Intensive Care Med. 2010. PMID: 19756498 Free PMC article. Review.

5

Persistently low plasma thioredoxin is associated with meningococcal septic shock in children.

Callister ME, Burke-Gaffney A, Quinlan GJ, Betts H, Nadel S, Evans TW. Callister ME, et al. Intensive Care Med. 2007 Feb;33(2):364-7. doi: 10.1007/s00134-006-0460-7. Epub 2006 Nov 18. Intensive Care Med. 2007. PMID: 17115131

6

Sepsis since the discovery of Toll-like receptors: disease concepts and therapeutic opportunities.

Leaver SK, Finney SJ, Burke-Gaffney A, Evans TW. Leaver SK, et al. Crit Care Med. 2007 May;35(5):1404-10. doi: 10.1097/01.CCM.0000261883.16943.4B. Crit Care Med. 2007. PMID: 17414083 Review.

7

Extracellular thioredoxin levels are increased in patients with acute lung injury.

Callister ME, Burke-Gaffney A, Quinlan GJ, Nicholson AG, Florio R, Nakamura H, Yodoi J, Evans TW. Callister ME, et al. Thorax. 2006 Jun;61(6):521-7. doi: 10.1136/thx.2005.053041. Epub 2006 Apr 6. Thorax. 2006. PMID: 16601094 Free PMC article.

8

PMX464, a thiol-reactive quinol and putative thioredoxin inhibitor, inhibits NF-kappaB-dependent proinflammatory activation of alveolar epithelial cells.

Callister ME, Pinhu L, Catley MC, Westwell AD, Newton R, Leaver SK, Quinlan GJ, Evans TW, Griffiths MJ, Burke-Gaffney A. Callister ME, et al. Br J Pharmacol. 2008 Nov;155(5):661-72. doi: 10.1038/bjp.2008.258. Epub 2008 Jun 30. Br J Pharmacol. 2008. PMID: 18587424 Free PMC article.

9

Modulation of cell adhesion molecule expression and function on human lung microvascular endothelial cells by inhibition of phosphodiesterases 3 and 4.

Blease K, Burke-Gaffney A, Hellewell PG. Blease K, et al. Br J Pharmacol. 1998 May;124(1):229-37. doi: 10.1038/sj.bjp.0701833. Br J Pharmacol. 1998. PMID: 9630364 Free PMC article.

10

Tumour necrosis factor-alpha-induced ICAM-1 expression in human vascular endothelial and lung epithelial cells: modulation by tyrosine kinase inhibitors.

Burke-Gaffney A, Hellewell PG. Burke-Gaffney A, et al. Br J Pharmacol. 1996 Nov;119(6):1149-58. doi: 10.1111/j.1476-5381.1996.tb16017.x. Br J Pharmacol. 1996. PMID: 8937718 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results